.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Set up watchlists for daily email updates

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Harvard Business School
Covington
Baxter
UBS
McKesson
AstraZeneca
Federal Trade Commission
Mallinckrodt
Express Scripts

Generated: June 23, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 050814

« Back to Dashboard
NDA 050814 describes CAYSTON, which is a drug marketed by Gilead and is included in one NDA. It is available from one supplier. There are four patents protecting this drug. Additional details are available on the CAYSTON profile page.

The generic ingredient in CAYSTON is aztreonam. There are eight drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the aztreonam profile page.

Summary for NDA: 050814

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 050814

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CAYSTON
aztreonam
FOR SOLUTION;INHALATION 050814 NDA Gilead Sciences, Inc. 61958-0901 61958-0901-1 2 CARTON in 1 PACKAGE (61958-0901-1) > 1 KIT in 1 CARTON * 1 mL in 1 VIAL * 1 mL in 1 AMPULE

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:FOR SOLUTION;INHALATIONStrength75MG/VIAL
Approval Date:Feb 22, 2010TE:RLD:Yes
Patent:7,214,364Patent Expiration:Dec 20, 2021Product Flag?YSubstance Flag?Delist Request?
Patent:7,208,141Patent Expiration:Dec 20, 2021Product Flag?YSubstance Flag?Delist Request?
Patented Use:IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA
Patent:7,427,633Patent Expiration:Dec 20, 2021Product Flag?YSubstance Flag?Delist Request?
Patented Use:IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
McKinsey
Harvard Business School
Boehringer Ingelheim
AstraZeneca
Mallinckrodt
Federal Trade Commission
US Army
Teva
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot